tumor (according to National Cancer Institute risk criteria) with a high dose chemotherapy protocol using carboplatin (400 mg/ m2/day -5 to -3), VP 16 (400 mg/m2/day -5 to -3), ifosphamide (2.5 g/m2/day -5 to -3), PBSC transplantation (day 0) and G-CSF administration (from days 0 to 14). It is known that these patients usually die within 24 months if the conventional (regular-dose) chemotherapy is undertaken. The clinical effect of this therapy revealed 2 CRs and 3 PRs (Table 2) 
Gastric Cancer Chemotherapy
Society for Gastric Cancer took these circumstances into consideration, and devised a newevaluation methodto provide an objective and precise wayto assess the therapeutic efficacy of chemotherapy based on the roentgenographic or endoscopic changes. Generally, it is desirable for the efficacy of chemotherapy to be evaluated from X-ray and endoscopic findings if a primary tumor is present.
These new criteria for the evaluation of chemotherapy for gastric cancer are easy to apply, and were designed with consideration of organ-specific properties following the principles of the Japanese Criteria for the Evaluation of the Direct Effects of Cancer Chemotherapy for Solid Tumors. The efficacy is evaluated on the basis of the rate of regression of measurable lesions, as is described in "Reporting of Response" in the WHOHandbook for Reporting Results of Cancer Treatment.
The following is the Criteria for Evaluating Efficacy of Chemotherapy/Radiation Therapy in the Treatment of Gastric Cancer established by the Japanese Research Society for Gastric Cancer, which are described in the 12th Revised Version of the General Rules for the Gastric Cancer Study. These criteria classify the primary foci of inoperable gastric cancer into three subtypes by X-ray or endoscopic findings: measurable lesion (a-lesion), not measurable but evaluable lesion (b-lesion) and diffusely infiltrated lesion (c-lesion). Complete response (CR) is defined as disappearance of tumor on X-ray or endoscopy for a minimumof4 weeks. According to the three subtypes, CRof each lesion is noted as aCR, bCRand CCR,respectively. aPR (partial response) requires a minimumof a 50%reduction in the sumof the products of the greatest perpendicular diameters of measurable lesions. bPRrequires a marked regression and flattening of an elevated or ulcerated lesion (an estimated decrease of more than 50%) on X-ray or endoscopy for a minimum of 4 weeks. CPRrequires a minimum of a 50% enlargement of the affected area on X-ray for a minimumof 4 weeks. aNC(no changes) and bNC are defined as no change in comparisonwith pretreatment findings or no changessuitable to be categorized as PR for a minimumof 4 weeks. CNCis defined as less than a 50%enlargement of the affected area on X-ray for a minimum of4 weeks. aPD (progressive disease) and bPD are defined as a 25%or greater increase of an a-lesion and an estimated 25%or greater increase of a b-lesion on X-ray or endoscopy, respectively. CPDis defined as tumor progression detected by X-ray examination. The present response criteria for a metastatic lesion are nearly the same as the WHO criteria.
//. Randomized controlled trials of phase III study Despite the many reports of chemotherapy trials for inoperable or recurrent gastric cancer in Japan, the results unfortunately have not met the international criteria for chemotherapy of gastric cancer whenreviewed extramurally. For ten years, we have conducted three multiinstitutional, randomized, controlled trials with extramural review by adhering strictly to the aforementioned response criteria. In 198 1 , the median survival of patients with the same cancer types treated with chemotherapy was reported by Kurihara to be 10 months for Recently, two or three combination therapies including cisplatin with a high response rate was used in gastric cancer chemotherapy.
5 ' -deoxy-5-fluorouridine (5 ' -DFUR, doxifluridine) has been developed as a prodrug for oral 5-fluorouracil (5-FU), which has been used clinically in Japan for the treatment of gastric, colorectal, and breast cancers. Therefore a multicenter study to seek a moreeffective istration and 3-days withdrawal/week plus CDDP:80mg/m2 day, q 3 weeks, andregimenB was 5'-DFUR: 1 ,400mg/m2/day, 4-days administration and 10-days withdrawal/every 2 weeks plus CDDP: 80mg/m2 day, day 5, q 4 weeks. The overall response rate for Regimen A was 40% (95% CI, 20.8-59.2%) and that for Regimen B was 36.4% (95% CI, 22.7-50.1%).
Quality of life evaluation
The quality of life (QOL) of patients undergoing chemotherapy is an important clinical endpoint. Changes of QOLwith time in patients who had undergone abovementioned 5'-DFUR+CDDP for inoperable gastric cancers were investigated. The items studied included appetide, general feeling, sleep, fatigue, pain, family understanding and cooperation, association with friends and colleagues, anxiety concerning the disease, expectations of treatment and daily life activities.
These 10 items were recorded by the patients for 2-4 weeks in five grades by a combination of the analog scale and category scale method. Moreover, the analog scale, 10 cm in length about "feeling" was also checked at the same time. By chance we could compare the change in the 10 items in the QOLquestionnaires between Regimen A and Regimen B. A remarkable difference between Regimen A and Regimen B was recognized for appetite, general feeling, fatigue, expectations of treatment and the analog scale about "feeling" based on the followup data of the QOLquestionnaire. As a result, from the point of QOL, RegimenB is considered to be muchbetter than RegimenA.
In the near future, Leucovorin plus 5-FU and CPT-1 1 are expected to be used for advanced gastric cancers. Someexperimental evidence has revealed that the increase of tumor blood flow was observed in all tumors arising from various organs and various types of histology (2, 3) and that the chemotherapeutic inhibitory effects on tumor growth in the liver and the peritoneum were enhanced under AII hypertension (4, 5). By comparison of Computed Tomography (CT) values in region of interests (ROIs) using dynamic CT, the enhancement of contrast media in the tumorarea was clearly elevated under A II hypertension (6). The results of a cooperative, randomized, controlled trial for advanced gastric carcinoma showeda significant enhancement in the anti-cancer effects in the IHC-treated group compared with that of the non-IHC group which received ordinary iv treatment under normotension (7). The frequency and grade of the side effects of the anti-cancer drugs were not statistically different between the IHC and non-IHC groups. Moreover, pathohistological effects on the tumor tissues were evidently augmented in the gastrectomy-receiving patients of the IHC grpup. According to the criteria of the General Rules for the Stomach Cancer Study, one case of grade 3, 2 of grade 2, 3 of lb, and 2 of 1a were obtained in the IHC group, while one of lb, 3 of la, and 2 of zero were obtained in the non-IHC group (8).
The procedure of IHC has been previously described elsewhere (9).
Therewere someaccompanying symptoms such as a sense of chest oppression and headache whenthe blood pressure was only elevated, but they were not so severe that the IHC couldnot be performed in nearly all the cases. But, careful attention to control the blood pressure values must be paid to avoid excess 
